Navigation Links
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Date:10/12/2009

a, including M. tuberculosis, M. avium complex, and M. avium subspecies paratuberculosis, the potential etiological agent of Crohn's disease. SQ641 also has the potential to be effective on additional clinically relevant bacteria. Sequella licensed the compound library from Daiichi-Sankyo (November 2004). Daiichi-Sankyo identified the compound class and performed extensive research and preliminary preclinical development on several drug leads. Sequella has exclusive rights to the series of TL-1 inhibitors for the treatment of TB and all other indications for nearly every worldwide market.

As announced in September 2008, Sequella also received a 3-year, $2.3 Million NIH Phase 2 SBIR grant for development of SQ641 as an antibiotic for treatment of tuberculosis. Approval for funding the 2nd year of this grant, $795,701, was received in early September 2009.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The National Institutes of Health (NIH) -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
2. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
3. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
4. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
5. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
6. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
7. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
8. Sinovac Obtains Production License for H1N1 Vaccine
9. Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 ... is designed to introduce cutting edge communication technology, ... of platform upgrades. This webinar series demonstrates online ... quest to leverage web conferencing’s most innovative and ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... , , , SAN ... announced today that the Company has entered into a Committed Equity Financing ... terms of the agreement, Kingsbridge has committed to provide up to $75 ... the purchase of newly-issued shares of Neurocrine common stock. , ...
... Ne u r ona s ce nt, ... novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer,s, Parkinson,s and other neurodegenerative diseases, ... Life Sciences Summit 2009 -- S h o w c ... Pr o m oting C ...
... , , , ... Technologies Inc. ("EAU" or "Company") (OTC Bulletin Board: EAUI), a ... today that the company has completed a trial with a ... use of electrolyzed water technology as a sanitation process for ...
Cached Biology Technology:Neurocrine Biosciences Secures Committed Equity Financing Facility 2Neurocrine Biosciences Secures Committed Equity Financing Facility 3Neuronascent to Present at Life Sciences Summit 2009 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
(Date:12/15/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Recognition Market 2015-2019" report to their offering. ... recognition is a technology used for the identification of ... of a person such as nose, jaw edges, mouth, ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... name of a new species of hermit crab recently discovered ... Christopher Tudge, a biology professor at American University in Washington, ... life, from boyhood trips to the beach collecting crustaceans in ... zoology and biology at the University of Queensland. He has ...
... researchers report concrete steps in the use of human stem ... success highlights a pathway toward faster, cheaper drug development for ... a therapy,s safety and effectiveness on cultured clones of a ... article published November 25 on the website of the journal ...
... 2012) The Algae Biomass Organization, the trade association for the ... of California at San Diego study that concludes, for the ... capable as freshwater algae in producing biofuels. The research is ... issue of the scientific journal Algal Research . ...
Cached Biology News:American University biologist discovers new crab species 2American University biologist discovers new crab species 3Study advances use of stem cells in personalized medicine 2Algae Biomass Organization hails new UCSD study showing saltwater algae viable for biofuels 2
... basic power supply are used for submerged horizontal ... This Model 96 cell includes a buffer tank, ... with fluorescent ruler, and a gel caster. The ... provides output of 10-300 V, 4-400 mA, and ...
... The Sub-Cell Model 192 and PowerPac basic power ... of nucleic acids in agarose gels. This Model ... x 15 cm UV-transparent gel tray with fluorescent ... power supply, 100-120 and 220-240 V, provides output ...
... The Sequi-Gen GT and PowerPac 3000 system, 220-240 ... a 38 x 30 cm vertical slab gel ... electrophoresis cell, which is capable of separating nucleic ... integral plate chamber (IPC) assembly (IPC and bonded ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
Biology Products: